# US 2009/0025106 A1 · C-terminally truncated interferon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0025106 A1
- Document ID: US20090025106A1
- Status: Published application
- Kind: A1
- Application number: 11/874,607
- Filed: 2007-10-18
- Published: 2009-01-22
- Earliest claimed: 2004-07-29
- Assignees: Large Scale Biology Corporation
- Inventors: Stephen J. Reinl; Gregory P. Pogue
- Web page: https://patentgrep.com/patent/US20090025106A1

## CPC

- C12N 15/8221: {Transit peptides}
- C07K 14/56: IFN-alpha
- C12N 15/8257: {for the production of primary gene products, e.g. pharmaceutical products, interferon}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention described herein provides a C-terminally truncated interferon having enhanced biological activity and the polynucleotides encoding such interferon. Also provided are methods for producing and using such truncated interferon.

## Claims

### Claim 1

An artificial polynucleotide encoding a polypeptide comprising a C-terminally truncated interferon having enhanced biological activity.

### Claim 2 (depends on 1)

The artificial polynucleotide of claim 1 further comprising a nucleotide sequence that encodes the amino acid sequence of an extensin signal peptide.

### Claim 3 (depends on 1)

The artificial polynucleotide of claim 1, wherein said polynucleotide is a fragment of SEQ ID NO:1 selected from the group consisting of nucleotides 1-468, nucleotides 1-471, and nucleotides 1-474.

### Claim 4 (depends on 3)

The artificial polynucleotide of claim 3 wherein the nucleotide sequence that encodes the amino acid sequence of an extensin signal peptide is linked to the 5′ end of the polynucleotide encoding the C-terminally truncated interferon.

### Claim 5

A host cell comprising an expression vector wherein said vector comprises an artificial polynucleotide encoding a polypeptide comprising a C-terminally truncated interferon having enhanced biological activity.

### Claim 6 (depends on 5)

The host cell of claim 5 wherein the host cell is selected from the group consisting of a plant cell and a bacterial cell.

### Claim 7

A process for producing a polypeptide comprising a C-terminally truncated interferon having enhanced biological activity comprising transforming a plant with an expression vector wherein said vector comprises an artificial polynucleotide encoding a poly peptide comprising a C-terminally truncated interferon.

### Claim 8 (depends on 7)

The process of claim 7 comprising infecting the plant with a viral vector comprising the expression vector.

### Claim 9 (depends on 7)

The process of claim 7 wherein the expression vector further comprises a nucleotide sequence that encodes the amino acid sequence of an extensin signal peptide.

### Claim 10 (depends on 7)

The process of claim 7 comprising stably incorporating the expression vector into the genome of the plant.

### Claim 11

A plant comprising an expression vector wherein said vector comprises an artificial polynucleotide encoding a polypeptide comprising a C-terminally truncated interferon having enhanced biological activity.

### Claim 12 (depends on 11)

The plant of claim 11 wherein the expression vector is a viral vector.

### Claim 13 (depends on 11)

The plant of claim 11 wherein the expression vector is stably incorporated into the plant genome.

### Claim 14 (depends on 11)

The plant of claim 11, wherein said plant expresses a C-terminally truncated interferon having enhanced biological activity.
